<DOC>
	<DOCNO>NCT01105390</DOCNO>
	<brief_summary>This phase II trial study well give AMG 102 together pemetrexed disodium cisplatin work treat patient malignant pleural mesothelioma . Monoclonal antibody , AMG 102 , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , pemetrexed disodium cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving AMG 102 together pemetrexed disodium cisplatin may kill tumor cell</brief_summary>
	<brief_title>AMG 102 , Pemetrexed Disodium , Cisplatin Treating Patients With Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate progression-free survival patient malignant pleural mesothelioma ( MPM ) treat anti-HGF monoclonal antibody AMG 102 combination pemetrexed disodium cisplatin . SECONDARY OBJECTIVES : I . To assess toxicity associate regimen patient . II . To determine response rate patient treat regimen . III . To determine overall survival patient treat regimen . IV . To evaluate multiple potential correlative biomarkers MPM relevant combine regimen , include serum HGF mesothelin level , c-met expression IHC tumor specimen , presence c-met mutation tumor , presence thymidylate synthetase ( TS ) excision repair cross complement protein-1 ( ERCC1 ) polymorphism . OUTLINE : This multicenter study . Patients receive anti-HGF monoclonal antibody AMG 102 ( AMG 102 ) IV 1 hour , pemetrexed disodium IV 10 minute , cisplatin IV 1 hour day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients without disease progression may continue AMG 102 IV 1 hour day 1 , every 3 week , maintenance therapy absence disease progression . Some patient undergo blood sample collection baseline periodically study correlative biomarker study . Tumor sample diagnostic tissue may also analyze . After completion study therapy , patient follow periodically every 3 month 2 year every 6 month 1 year .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm malignant mesothelioma pleura All subtypes allow Disease amenable curative surgery Measurable disease Patients disease measurable standard RECIST criterion ( i.e. , pleural rinds/thickening ) allow Pleural effusion positive bone scan consider measurable No prior radiotherapy target lesion measurable lesion unless site subsequent evidence progression Patients undergone pleurodesis allow Postpleurodesis CT scan require No known suspect brain metastasis ECOG performance status 01 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 1.5 time ULN ALT AST ≤ 1.5 time ULN Albumin ≥ 2.5 g/dL Creatinine clearance ≥ 45 mL/min OR serum creatinine ≤ 1.5 time ULN Able take folic acid vitamin B12 Not pregnant nursing Negative pregnancy test Fertile patient must agree use effective contraception No active infection serious concomitant systemic disorder compatible study No thrombosis vascular ischemic event within last 12 month , include follow : Deep venous thrombosis Pulmonary embolism Transient ischemic attack Cerebral infarction Myocardial infarction No peripheral edema ≥ grade 3 No serious nonhealing wound No second primary malignancy except situ carcinoma cervix breast , situ malignancy , adequately treat basal cell carcinoma skin , malignancy within past 3 year evidence recurrence No concurrent antiretroviral therapy HIVpositive patient At least 4 week since prior radiotherapy More 30 day since major surgery procedure &gt; 14 day since minor surgical procedure recover Central venous catheter placement , fineneedle aspiration , thoracentesis , paracentesis consider major minor surgical procedure No prior systemic chemotherapy mesothelioma No prior intracavity cytotoxic drug immunomodulators ( unless purpose pleurodesis ) No prior antiHGF monoclonal antibody AMG 102 , cMET , HGF inhibitors No prior concurrent anticoagulation therapy within past 7 day Lowdose Coumadintype anticoagulant lowmolecular weight heparin prophylaxis central venous catheter thrombosis allow No investigational agent within past 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>